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A B S T R AC T
Background: Serum TGF-β1 concentrations are 
reported to be elevated in chronic fatigue syndrome 
(CFS). However, measurement of circulating cytokines 
is a complex procedure and control of pre-analytical 
procedures is essential. The objective of the current study 
was to measure circulating TGF-β1 concentrations in CFS 
patients compared to healthy controls, taking into account 
differences in pre-analytical procedures.
Methods: Two cohorts of female CFS patients were 
included. In both studies patients were asked to bring a 
healthy, age-matched control. At baseline, TGF-β1 levels 
were measured in plasma and additionally P-selectin, a 
marker of platelet activity, was determined in a subgroup 
of participants. 
Results: 50 patients and 48 controls were included in 
cohort I, and 90 patients and 29 controls in cohort II. 
Within the cohorts there were no differences in TGF-β1 
concentrations. However, between the cohorts there was 
a large discrepancy, which appeared to be caused by 
differences in g-force of the centrifuges used. The lower 
g-force used in cohort II (1361 g) caused more platelet 
activation, reflected by higher p-selectin concentrations, 
compared to cohort I (p < 0.0001), which was confirmed in 
a second independent experiment. There was a correlation 
between TGF-β1 and p-selectin concentrations (r 0.79, 
p < 0.0001).
Conclusion: These results demonstrate that control of 
pre-analytical procedures is an essential aspect when 
measuring circulating cytokines. No evidence for 
enhanced TGF-β1 in patients with CFS was found.
K E Y WOR DS
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I N T RODUC T I ON
Chronic fatigue syndrome (CFS) is an enigmatic disorder, 
in which patients suffer from incapacitating fatigue, pain 
and a series of associated symptoms.1 The complaints 
are not due to any known underlying disease, and the 
pathophysiology has not been elucidated. CFS may be 
provoked by infections such as infectious mononucleosis, 
or by any of a series of other triggers. Because of the 
association with preceding infection and the similarities 
in symptomatology with sickness behaviour that can be 
induced by proinflammatory cytokines,2 many studies 
aiming to find abnormal cytokine regulation have been 
performed on CFS.3 The picture that emerges from 
these studies is by no means consistent. In publications 
the reasons for the discrepancies found often remain 
unclear, but it seems likely that factors like age and 
gender of the patients, composition of the control groups, 
the robustness of the pre-analytical procedures (such 
as sampling, handling, centrifugation and storage) 
and the kind of assays used, play an important role. In a 
recent systematic review on cytokines in CFS 3, the most 
consistent finding was elevation of the anti-inflammatory 
cytokine transforming growth factor β (TGF-β).
Recently we performed a large prospective cytokine study 
in female CFS patients.4 This study was methodologically 
robust, as the age- and gender-matched controls from 
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the patients’ neighbourhood were recruited and bled 
at the same time and in the same place as the patients. 
In this way the pre-analytical handling of the samples was 
exactly the same. The results of this study, in which 92 
inflammatory markers were measured simultaneously, 
have been published elsewhere.4 In another cohort of CFS 
patients and similarly matched controls, we also sampled 
blood to measure inflammatory markers.5 In the present 
report we demonstrate the relevance of stringent methods 
of controlling for variability that may arise during the 
pre-analytical phase. To this end we describe the results of 
TGF-β1 measurements in these two CFS cohorts.
MAT E R I A L S  A N D  M E T HODS
Patients
Two cohorts of patients with CFS were enrolled in this 
study. The first cohort (cohort I) consisted of patients 
who participated in a double-blind randomized controlled 
trial (RCT) on the effect of IL-1 inhibition on CFS-related 
symptoms.6 The study was conducted at the Department of 
Internal Medicine and Expert Centre for Chronic Fatigue 
(ECCF) of the RadboudUMC, Nijmegen, the Netherlands. 
Details of the study were described elsewhere.6,7 In short, 50 
female patients aged between 18 and 59 were enrolled, who 
fulfilled the Center for Disease Control (CDC) criteria for 
CFS.1 Use of medication was not allowed, oral contraceptives 
and paracetamol excepted. Each of the patients was asked to 
bring a healthy female neighborhood control in her own age 
range (± 5 years), to their first study visit. The second cohort 
(cohort II) consisted of 90 female patients between 18 and 
65 years fulfilling the CDC criteria for CFS. The criteria 
for inclusion and exclusion have been described in detail 
elsewhere.5 Just as with Cohort I, a proportion of patients 
was asked to bring a healthy female neighborhood control 
matched for age and gender to their first study visit.
All participants provided written and oral informed 
consent before inclusion. The hospitals’ ethics committee 
(Commissie Mensgebonden Onderzoek Regio Arnhem/
Nijmegen) approved the study protocols (2014/025 and 
2013/113). The study was performed in accordance with the 
declaration of Helsinki.
Questionnaires
Fatigue was measured in both patients and controls using 
the fatigue severity subscale of the checklist individual 
strength (CIS), which has been used frequently with CFS 
patients.8 Scores on the CIS-f run from 8 to 56, a score ≥ 35 
reflecting severe fatigue. 
Blood collection
Blood samples were collected at baseline at the outpatient 
clinic for Internal Medicine at the RadboudUMC in 
Nijmegen, the Netherlands from all patients of Cohort I. 
Samples of controls were collected simultaneously with 
those of patients. Venous blood was collected in EDTA 
tubes, and kept on ice until centrifugation, which was 
performed within 2-3 hours (2959 g). Plasma aliquots were 
then kept frozen at -80°C for maximally 2 years. For Cohort 
II, the sampling, handling (centrifugation speed 1361 g) 
and storage of the blood of patients and controls were done 
in similar fashion at the Donders Centre for Neuroimaging 
in Nijmegen, the Netherlands. 
Measurements of TGFβ1 and P-selectin
Total TGF-β1 levels were measured by enzyme-linked 
immunosorbent assay (ELISA), as previously described in 
detail (R&D systems).9 All samples were acid activated to 
activate latent TGF-β (1 M hydrochloric acid, 30 min, room 
temperature, neutralization with 1M NaOH, followed by 
direct analysis). All assays were performed on the same day 
using the same reagents.
P-selectin was measured in a proportion of samples by 
ELISA (R&D systems) according to the instructions of the 
manufacturer.
Confirmation experiment
For a second experiment, two EDTA venous blood samples 
were taken from 5 healthy controls at the same time 
point. Samples were handled in similar fashion, the only 
difference being the g-force used for plasma centrifugation. 
One sample from each participant was centrifugated at a 
speed of 2959 g and one at 1361 g. Subsequently platelet 
numbers were measured in all samples.
Statistical analysis
Study data were analyzed using IBM SPSS statistic package 
version 22. All continuous variables are presented as 
means and standard deviations (SD)/ standard error of the 
mean (SEM). For group comparison a Students T-test was 
used. Pearson’s correlation was used for the correlation 
between TGF-β and P-selectin. 
R E SU LT S
Baseline characteristics
As displayed in table 1, age did not differ significantly 
between patients and controls of both groups. As expected, 
patients had higher fatigue scores compared to controls 
(51.5 vs 19.1, p < 0.001), but there were no differences 
between cohort I and II.
TGF-β1 and P-selectin
The results of the TGF-β1 measurements in the patients 
and controls from Cohort I are depicted in figure 1A. 
No differences in TGF-β1 concentrations were found 
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between patients and healthy controls. Likewise, the 
results of the measurements in Cohort II did not reveal 
differences between CFS patients and controls (figure 1B). 
However, there was a large differences in the TGF-β1 
concentrations found between Cohort I and Cohort II. 
As it is known that platelets are a rich source of TGF-β,10 
we wondered whether the higher TGF-β1 levels could 
be caused by a higher number of (activated) platelets in 
Cohort 2. To explore whether platelet activation differed 
between the two groups, we measured P-selectin as a 
platelet marker in a random selection of samples.11 The 
concentration of P-selectin differed greatly between the two 
cohorts (p < 0.001; figure 2). There was a strong correlation 
(r 0.79, p < 0.0001) between the concentrations of TGF-β1 
and P-selectin. Differences in platelet activation could be 
explained by differences in the g-force of the centrifuges 
used at the two study locations. 
Confirmation experiment
Platelet counts were significantly lower in the samples 
centrifugated at the highest g-force of 2959 g (1.4 ± 0.5 x 10 
^ 3/μl vs. 132.2 ± 16.45 x 10 ^ 3/μl, p < 0.001).
Table 1. Baseline characteristics of chronic fatigue syndrome patients and healthy controls
Cohort I Cohort II
CFS (n = 50) HC (n = 48) CFS (n = 91) HC (n = 29)
Age (years) 31 (10)* 31 (10) 34 (11) 33 (11)
Fatigue severity (CIS-f) 52 (4) 20 (11) 51 (4) 17 (7)
* ( ): standard deviation
Figure 1. TGF-β1 concentrations for patients and controls in cohort I and cohort II
Figure 2. P-selectin concentrations for a proportion of 
patients of cohort I (n = 35) and cohort II (n = 35)
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D I S CUS S I ON
In this report we demonstrate that even with scrupulous 
methodology, inaccurate results may be obtained. It turned 
out that the different properties of the centrifuges used at 
the two study locations were responsible for differences 
in platelet numbers and platelet activation (as assessed by 
P-selectin measurements).
Although it is well known that platelets contain 
considerable amounts of TGF-β,10,12 this is often not taken 
into account when measuring circulating concentrations 
of this cytokine. Many cytokine studies do not adequately 
describe the pre-analytical procedures of patient samples 
and controls. 
In a recent study on TGF-β1 in CFS patients a pitfall 
similar to the one in the present paper was encountered. 
In this otherwise carefully performed study differences 
in the duration of centrifugation between two technicians 
explained the differences found in TGF-β1 between 
patients and controls.13 Our current data show that if, for 
example, samples of the controls of cohort I would have 
been prepared like those of cohort II, strong differences 
could have been observed, which would not have been due 
to actual differences caused by the underlying disease but 
solely to sample handling. 
The use of different sample collections for patients and 
controls is fairly common. This was in fact the case in 
the studies that incriminated the retroviruses XMRV and 
XMLV.14,15 It led to results that misled both the scientific 
community and more sadly, the patients suffering from 
CFS.16
In conclusion, we want to make a plea for better 
standardization of pre-analytical sample handling for 
patient studies, not only in CFS research. The use of 
neighborhood controls who are bled at the same time and 
location, whose samples undergo the exact same procedure 
as those of the patients, is a good way of enhancing the 
quality of such research. In addition, precise reporting 
on the nature of the control group and the pre-analytical 
procedures followed with controls and patients is essential.
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